|Bid||4.85 x 900|
|Ask||4.96 x 1100|
|Day's Range||4.6500 - 4.9033|
|52 Week Range||2.4000 - 9.6110|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.33|
NEW YORK, Feb. 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company's Phase III registration trial of MicroPine to reduce the progression of myopia in children. Currently, there are no FDA-approved therapies to slow the progression of myopia, a condition that, if uncontrolled, can in some cases be associated with major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment.
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / In January, the trend in biotech stocks appeared to be on a positive sloping trajectory as the IBB capped off its strongest month in almost a year. Below ...
HENDERSON, NV / ACCESSWIRE / January 31, 2019 / Below are a few biotechnology stocks seeing a growing amount of investor interest which is the precursor for long term bull runs. One company who's on the ...
With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
Shares of biotech Eyenovia Inc. rose 78% in premarket trade Wednesday, after the company reported positive results in a late-stage trial of a device that causes dilation of the eye. The New York-based company said results from the MicroStat Phase 3 MIST-1 study showed a statistically and clinically superior effect using a fixed-combination formulation than either component formulation. "We believe this is the first time in a Phase III FDA registration program that drugs have been delivered to the ocular surface using a smart microdose eyedropper-free delivery system -- a meaningful step forward as we try to modernize the legacy eyedropper paradigm," Eyenovia CEO and chief medical officer Sean Ianchulev said in a statement. The treatment is expected to make in-office eye exams easier and more efficient.
Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from the MicroStat Phase 3 MIST-1 study. The study examined the safety and efficacy of the Company’s first-in-class, MicroStat fixed-combination formulation, with target markets including the estimated 80 million annual pharmacologic mydriasis market in the United States.
A look at the shareholders of Eyenovia, Inc. (NASDAQ:EYEN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Eyenovia Inc (EYEN), Teladoc Inc (TDOC), and Allscripts Healthcare Solutions, Inc. (MDRX), are four healthcare stocks worth paying attention to the healthcare industry presses onward. Premier Health Group, Inc (OTC:PHGRF) (CSE:PHGI) a company that is dominating the telehealth sector of the healthcare industry, has seen a strong month of bullish trading, with shares of the company climbing as much as 31% in a 30-day period. The Company has enjoyed impressive growth following their announcement earlier this week regarding the company's signing into a binding LOI to acquire all of the outstanding securities of Cloud Practice Inc.
Eyenovia, Inc. (“Eyenovia” or the “Company”) (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, has priced its underwritten public offering of 1,200,000 shares of common stock at an offering price of $2.45 per share. All of the shares are being offered by the Company. The Company expects to receive gross proceeds from the offering, excluding the exercise of the over-allotment option, if any, of approximately $2.9 million, excluding underwriting discounts and commissions and other offering-related expenses.
Eyenovia, Inc. (EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first patient in its second Phase III study, the MIST-2 trial, for the Company’s Phase III MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer commented, “We are pleased to have swiftly completed enrollment in the Phase III MIST-1 study, our first pivotal trial of MicroStat for pharmacologic mydriasis, in line with our recruitment expectations.
Eyenovia, Inc. (EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-review journal Clinical Ophthalmology. The topline results of the study were first reported by the Company earlier this year. This is the first study to demonstrate the effect of Eyenovia micro-dose on intraocular pressure (IOP) lowering, which is the main treatment paradigm for conditions such as glaucoma.
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
NEW YORK, Nov. 26, 2018 /PRNewswire/ -- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III trials (MIST-1 and MIST-2) of the Company's MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. The studies will investigate the safety and efficacy of the Company's first-in-class fixed-combination phenylephrine 2.5% - tropicamide 1% ophthalmic solution, administered as a micro-dose using the Optejet™ dispenser. Pharmacologic mydriasis is an important part of an estimated 80 million office-based comprehensive and diabetic eye exams performed each year in the United States and is essential for the standard dilated retinal fundoscopic examination.
SAN DIEGO , Oct. 5, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against: PPDAI Group Inc. (NYSE: PPDF) Menlo ...